



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8492

Title: Advances in Adjuvant Systemic Therapy for Non-Small-Cell Lung Cancer

Reviewer code: 02493594

Science editor: Gou, Su-Xin

Date sent for review: 2013-12-29 15:24

Date reviewed: 2014-01-06 23:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The paper is well organized and takes consideration state of the art with regard to adjuvant therapy of NSCLC. However, authors should: - Specify the incidence of side effects in the main study - Emphasize the advantage produced by the association cisplatin and vinca alkaloids compared to VP-16 in the study IALT (toxic deaths, dead long period, etc.). Finally, a typing error in the "UFT" section [This advantage (ws) was]



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8492

Title: Advances in Adjuvant Systemic Therapy for Non-Small-Cell Lung Cancer

Reviewer code: 01332768

Science editor: Gou, Su-Xin

Date sent for review: 2013-12-29 15:24

Date reviewed: 2014-01-07 20:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This systematic review for the treatment of Non-SCLC was well written and is ready for publication. Due to the highly aggressive nature of NSCLC and the ineffectiveness of other measures, the adjuvant therapy is a new hope for treatment of this disease. It would be nice if the authors could add some contents to discuss why the mortality of NSCLC was not significantly changed during the past several decades, despite all hard effort.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8492

Title: Advances in Adjuvant Systemic Therapy for Non-Small-Cell Lung Cancer

Reviewer code: 02494535

Science editor: Gou, Su-Xin

Date sent for review: 2013-12-29 15:24

Date reviewed: 2014-01-19 01:55

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The authors revise extensively and clearly the literature on adjuvant treatment of NSCLC and state the current standard therapy in this setting. I only have minor comments. - They state the importance of stage but do not address the importance of histology. Though the latter is still not relevant at the moment for treatment decision in NSCLC it will likely become in the near future. Please address ongoing adjuvant studies as ITACA trial and ERCC1 targeted trial, the latter integrating both histology and biomarker data. - Please address the fact that age is not a contraindication to adjuvant chemotherapy as long as patient is fit, and relevant literature addressing this point